I-Mab (IMAB) - Total Liabilities
Based on the latest financial reports, I-Mab (IMAB) has total liabilities worth $18.50 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore IMAB net assets growth trend to track the company's year-over-year net asset growth rate.
I-Mab - Total Liabilities Trend (2017–2024)
This chart illustrates how I-Mab's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of I-Mab to measure how efficiently the company converts operating cash flow to free cash.
I-Mab Competitors by Total Liabilities
The table below lists competitors of I-Mab ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hubei Sanxia New Building Materials Co Ltd
SHG:600293
|
China | CN¥1.48 Billion |
|
Importadora y Exportadora de la Patagonia SA
BA:PATA
|
Argentina | AR$528.04 Billion |
|
Zhejiang Yuejian Intelligent Equipment Co Ltd
SHG:603095
|
China | CN¥654.98 Million |
|
BECE Legend Group Co Ltd
SHE:000803
|
China | CN¥3.76 Billion |
|
Servcorp Ltd
AU:SRV
|
Australia | AU$479.81 Million |
|
Eurocrane China Co Ltd
SHG:603966
|
China | CN¥2.33 Billion |
|
RADIANCE HLDGS GRP.HD-01
F:RDH
|
Germany | €62.18 Billion |
|
Intrepid Potash Inc
NYSE:IPI
|
USA | $143.34 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down I-Mab's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see IMAB market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how I-Mab's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for I-Mab (2017–2024)
The table below shows the annual total liabilities of I-Mab from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $11.52 Million | -98.71% |
| 2023-12-31 | $894.81 Million | -16.01% |
| 2022-12-31 | $1.07 Billion | +2.28% |
| 2021-12-31 | $1.04 Billion | +47.41% |
| 2020-12-31 | $706.65 Million | -81.27% |
| 2019-12-31 | $3.77 Billion | +13.25% |
| 2018-12-31 | $3.33 Billion | +151.37% |
| 2017-12-31 | $1.33 Billion | -- |
About I-Mab
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment o… Read more